Crinetics Pharmaceuticals, Inc. (CRNX) Stock Price

CRNXStock

$84.86+174.19%52W

Market Cap$9.00B

P/E—

PEG Ratio—

Div yield—

Beta0.02

CRNX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)83.87%

Price vs S&P 500 (4W)-1.95%

VGM Score65.99

Book Value / Share (Quarterly)$11.27

P/TBV (Annual)6.76x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)17.53%

Cash Flow / Share (Quarterly)$-4.02

Price vs S&P 500 (YTD)70.17%

Net Profit Margin (TTM)-1189.88%

EPS (TTM)$-5.05

10-Day Avg Trading Volume2.73M

EPS Excl Extra (TTM)$-5.05

Revenue Growth (5Y)156.00%

EPS (Annual)$-4.95

ROI (Annual)-46.90%

Gross Margin (Annual)86.02%

Net Profit Margin (5Y Avg)-10707.53%

Cash / Share (Quarterly)$11.40

Revenue Growth QoQ (YoY)2336.28%

ROA (Last FY)-41.32%

Revenue Growth TTM (YoY)2928.45%

EBITD / Share (TTM)$-5.46

ROE (5Y Avg)-38.69%

Operating Margin (TTM)-1302.52%

Cash Flow / Share (Annual)$-4.01

P/B Ratio7.51x

P/B Ratio (Quarterly)3.31x

Net Income / Employee (Annual)$-783,400

EV / Revenue (TTM)211.17x

ROA (TTM)-39.77%

EPS Incl Extra (Annual)$-4.95

Current Ratio (Annual)12.32x

Quick Ratio (Quarterly)15.36x

3-Month Avg Trading Volume3.17M

52-Week Price Return174.19%

Revenue / Employee (TTM)$71,000

Tangible BV / Share (Quarterly)$8.21

P/S Ratio (Annual)1163.94x

Asset Turnover (Annual)0.01x

52-Week High$84.81

Operating Margin (5Y Avg)-11677.88%

EPS Excl Extra (Annual)$-4.95

CapEx CAGR (5Y)97.86%

Tangible BV CAGR (5Y)84.80%

26-Week Price Return95.12%

Quick Ratio (Annual)12.09x

13-Week Price Return128.58%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)15.57x

Enterprise Value$8.90B

Revenue / Share Growth (5Y)104.27%

Asset Turnover (TTM)0.03x

Book Value / Share Growth (5Y)15.19%

Revenue / Employee (Annual)$13,000

Pretax Margin (Annual)-6043.88%

Cash / Share (Annual)$10.75

3-Month Return Std Dev196.70%

Net Income / Employee (TTM)$-844,500

ROE (Last FY)-46.90%

EPS Basic Excl Extra (Annual)$-4.95

Receivables Turnover (TTM)0.68x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-5.05

Receivables Turnover (Annual)2.52x

ROI (TTM)-44.22%

P/S Ratio (TTM)212.49x

Pretax Margin (5Y Avg)-10667.85%

Revenue / Share (Annual)$0.08

Tangible BV / Share (Annual)$5.87

Price vs S&P 500 (52W)155.88%

Year-to-Date Return82.13%

5-Day Price Return0.07%

EPS Normalized (Annual)$-4.95

ROA (5Y Avg)-34.62%

Net Profit Margin (Annual)-6046.22%

Month-to-Date Return1.51%

Cash Flow / Share (TTM)$-3.61

EBITD / Share (Annual)$-5.45

Operating Margin (Annual)-6714.77%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-38.69%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-5.05

P/TBV (Quarterly)3.90x

P/B Ratio (Annual)4.45x

Pretax Margin (TTM)-1189.45%

Book Value / Share (Annual)$10.38

Price vs S&P 500 (13W)125.79%

Beta0.02x

Revenue / Share (TTM)$0.40

ROE (TTM)-44.22%

52-Week Low$29.63

vGradeF

gGradeA

mGradeA

vgmGradeB

CRNX Earnings Surprise History

Q2 25-1.23est. -1.10

Q3 25-1.38est. -1.25

Q4 25-1.29est. -1.37

Q1 26-1.23est. -1.20

Q2 26-1.14est. -1.18

CRNX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.23

3.48

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$67.01

About Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals is a commercial-stage biopharmaceutical company developing treatments for rare endocrine diseases and endocrine-related tumors. Its lead product, Palsonify (paltusotine), is an FDA-approved once-daily oral treatment for acromegaly in patients with inadequate response to surgery or for whom surgery is not an option. The pipeline includes late-stage candidate atumelnant for adrenal disorders and CRN09682 targeting specific neuroendocrine tumors.